Gillian McGovern is an associate editor at Pharmacy Times®. She graduated from Rowan University in 2023 with a BA in Writing Arts and concentrations in Publishing & Writing for the Public, Technical & Professional Writing, and Creative Writing.
ENVISION Trial Results Show UGN-102 Has Long-Term Durability in Patients With Bladder Cancer
November 6th 2024Patients with low-grade intermediate-risk non-muscle-invasive bladder cancer who achieved a complete response rate after 3 months of UGN-102 treatment had an 82.3% duration of response at 12 months.
Read More
Human-Specific Genes Can Modify Expressions of Mutations That Lead to Neurodevelopmental Disorders
October 29th 2024The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.
Read More
FDA Grants Orphan Drug Designation to AND017 for the Treatment of Sickle Cell Disease
October 28th 2024Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.
Read More
FDA Grants Orphan Drug Designation to MDL-101 for Congenital Muscular Dystrophy Type 1a
Published: October 25th 2024 | Updated: October 25th 2024Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.
Read More
Real-World Evidence Presented at IDWeek Demonstrates Efficacy of CAB LA When Used for HIV PrEP
October 23rd 2024Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.
Read More